Hochschulschrift
Investigation of models with temporal and spatial interference in image based dosimetry of 177Lu-labelled radioligand therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Ludwig-Maximilians-Universität, Dissertation, 2016
- Schlagwort
-
Diagnose
Diagnostik
Differentialdiagnose
Pflegediagnose
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der Ludwig-Maximilians-Universität
- (wann)
-
2016
- Urheber
- Beteiligte Personen und Organisationen
-
Böning, Guido
- URN
-
urn:nbn:de:bvb:19-197144
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Delker, Andreas
- Böning, Guido
- Universitätsbibliothek der Ludwig-Maximilians-Universität
Entstanden
- 2016
Ähnliche Objekte (12)
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Influence of sampling schedules on dosimetry in radioligand therapies
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Influence of sampling schedules on dosimetry in radioligand therapies
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Influence of sampling schedules on dosimetry in radioligand therapies
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice
Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases